A Phase 3 interventional study of TX05 (trastuzumab) and Herceptin (trastuzumab) in HER2-positive Breast Cancer, Early-stage Breast Cancer and Breast Cancer, sponsored by Tanvex BioPharma USA, Inc.. Completed at 86 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-26.
Sponsored by Tanvex BioPharma USA, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 55th largest by enrollment of the 366 interventional ones that give a count, is one of 15 that started in 2019, is one of 60 in phase 3, and was the 278th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 15 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 338 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Tanvex BioPharma USA, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Tanvex BioPharma USA, Inc. has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an extension study to provide adjuvant treatment with single agent Herceptin or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles TX05 (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment. These subjects received TX05 on the TX05-03 study and continued to receive TX05 in this extension study.
Biological: TX05 (trastuzumab)
IV trastuzumab (Herceptin) TX05 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles Herceptin (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment. These subjects received Herceptin on the TX05-03 study and were randomized to receive Herceptin in this extension study.
Biological: Herceptin (trastuzumab)
IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles TX05 (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment. These subjects received Herceptin on the TX05-03 study and were randomized to receive TX05 in this extension study.
Biological: TX05 (trastuzumab)
Subjects will receive up to 13 cycles of adjuvant treatment.
Subjects will receive up to 13 cycles of adjuvant treatment.
Immunogenicity Assessments (ADA and Nab)
Samples for the evaluation of anti-drug antibodies (ADA), including neutralizing antibodies (Nab) were obtained before the administration of Cycle 1 (Week 0), Cycle 6 (Week 15), and the EOT/ET Visit. Only subjects with a positive ADA result were further tested for ADA cross-reactivity and Nab. Only subjects with a positive Nab result were further tested for Nab cross-reactivity.
Time frame: Assessed from first infusion through end of treatment (Week 45) or Early Termination visit. Each cycle is 3 weeks.
Disease-Free Survival
DFS, defined as the time from randomization in the neoadjuvant study (Protocol TX05-03) to the documentation of a first failure, where a failure was the recurrence of breast cancer or a diagnosis of a second primary cancer.
Time frame: Through study completion/end of treatment (Week 45).
Overall Survival
OS, defined as the time from randomization in the neoadjuvant study (Protocol TX05-03) until death from any cause.
Time frame: Through study completion/end of treatment (Week 45).
| Milestone | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) |
|---|---|---|---|
| Started | 175 | 82 | 81 |
| Completed | 165 | 77 | 77 |
| Not completed | 10 | 5 | 4 |
| Withdrew: Adverse event | 2 | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Withdrew: Subject refused to continue, ae and 2 patients only received 10 of 13 cycles | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 2 | 3 |
Samples for the evaluation of anti-drug antibodies (ADA), including neutralizing antibodies (Nab) were obtained before the administration of Cycle 1 (Week 0), Cycle 6 (Week 15), and the EOT/ET Visit. Only subjects with a positive ADA result were further tested for ADA cross-reactivity and Nab. Only subjects with a positive Nab result were further tested for Nab cross-reactivity.
| Participants | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) |
|---|---|---|---|
| Baseline — ADA Positive | 3 | 2 | 3 |
| Baseline — Nab Positive | 0 | 0 | 0 |
| Baseline — ADA Negative | 159 | 77 | 74 |
| Baseline — Not evaluated | 13 | 3 | 4 |
| Cycle 6 Week 15 — ADA Positive | 1 | 1 | 4 |
| Cycle 6 Week 15 — Nab Positive | 0 | 0 | 0 |
| Cycle 6 Week 15 — ADA Negative | 164 | 74 | 74 |
| Cycle 6 Week 15 — Not evaluated | 10 | 7 | 3 |
| End of Study/Early Terminiation — ADA Positive | 4 | 1 | 2 |
| End of Study/Early Terminiation — Nab Positive | 0 | 0 | 0 |
| End of Study/Early Terminiation — ADA Negative | 146 | 75 | 71 |
| End of Study/Early Terminiation — Not evaluated | 25 | 6 | 8 |
DFS, defined as the time from randomization in the neoadjuvant study (Protocol TX05-03) to the documentation of a first failure, where a failure was the recurrence of breast cancer or a diagnosis of a second primary cancer.
| Participants | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) |
|---|---|---|---|
| Recurrence of Breast Cancer or a Diagnosis of a Second Primary Cancer | 6 | 5 | 3 |
| No recurrence of Breast Cancer and No Diagnosis of a Second Primary Cancer | 160 | 73 | 76 |
| Discontinued form Study | 8 | 4 | 2 |
| No Post Baseline or No Evaluable Post Baseline | 1 | 0 | 0 |
| No Baseline or No Evaluable Baseline Assessment | 0 | 0 | 0 |
| Death | 0 | 0 | 0 |
OS, defined as the time from randomization in the neoadjuvant study (Protocol TX05-03) until death from any cause.
| Participants | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) |
|---|---|---|---|
| Last known alive | 175 | 82 | 80 |
| Lost to Follow-Up | 0 | 0 | 0 |
| Death | 0 | 0 | 1 |
Collected over Adverse Events were recorded from Day 1 (Week 0) of Cycle 1 of study treatment through End of Treatment (Week 45), with the exception of any ongoing study drug-related AEs, which were to be followed until the event was resolved, considered stable, or the investigator determined the AE was no longer clinically significant.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Product (TX05 Only) | 0/175 (0%) | 4/175 (2.3%) | 49/175 (28%) |
| Reference Therapy (Herceptin Only) | 0/82 (0%) | 3/82 (3.7%) | 15/82 (18.3%) |
| Test Product (Herceptin/TX05 Transition) | 1/81 (1.2%) | 2/81 (2.5%) | 15/81 (18.5%) |
| Event | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) |
|---|---|---|---|
| Hepatic failureHepatobiliary disorders | 0/175 | 0/82 | 1/81 |
| Ischaemic strokeNervous system disorders | 0/175 | 0/82 | 1/81 |
| Gastrointestinal infection/Infections and infestations | 0/175 | 1/82 | 0/81 |
| Femoral neck fracture/Injury, poisoning and procedural complications | 0/175 | 1/82 | 0/81 |
| COVID-19 pneumoniaInfections and infestations | 0/175 | 1/82 | 0/81 |
| Renal ColicRenal and urinary disorders | 0/175 | 1/82 | 0/81 |
| COVID-19Infections and infestations | 2/175 | 0/82 | 0/81 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/175 | 0/82 | 0/81 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/175 | 0/82 | 0/81 |
| Event | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) |
|---|---|---|---|
| Radiation Skin InjuryInjury, poisoning and procedural complications | 13/175 | 5/82 | 0/81 |
| Respiratory Tract InfectionInfections and infestations | 6/175 | 2/82 | 5/81 |
| HeadacheNervous system disorders | 9/175 | 5/82 | 3/81 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/175 | 5/82 | 2/81 |
| Alanine Aminotransferase IncreasedInvestigations | 10/175 | 2/82 | 1/81 |
| AstheniaGeneral disorders | 10/175 | 4/82 | 3/81 |
| Aspartate Aminotransferase IncreasedInvestigations | 9/175 | 1/82 | 3/81 |
| Age, Continuous(years) | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) | Total |
|---|---|---|---|---|
| Mean | 55.3 ± 11.43 | 53.7 ± 10.12 | 54.0 ± 10.71 | 54.6 ± 10.95 |
| Sex: Female, Male(Participants) | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) | Total |
|---|---|---|---|---|
| Female | 175 | 82 | 81 | 338 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 29 | 12 | 10 | 51 |
| Not Hispanic or Latino | 146 | 70 | 71 | 287 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 1 | 2 | 8 |
| Asian | 23 | 13 | 17 | 53 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 136 | 64 | 57 | 257 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 11 | 4 | 5 | 20 |
| Hormone Receptor Status(Participants) | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) | Total |
|---|---|---|---|---|
| Positive | 100 | 50 | 48 | 198 |
| Negative | 75 | 32 | 33 | 140 |
| Tumor Stage(Participants) | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) | Total |
|---|---|---|---|---|
| Stage IIa | 65 | 28 | 32 | 125 |
| Stage IIb | 78 | 41 | 35 | 154 |
| Stage IIIa | 32 | 13 | 14 | 59 |
| ECOG(Participants) | Test Product (TX05 Only) | Reference Therapy (Herceptin Only) | Test Product (Herceptin/TX05 Transition) | Total |
|---|---|---|---|---|
| Grade 0 | 142 | 56 | 64 | 262 |
| Grade 1 | 29 | 24 | 16 | 69 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 |
| Missing | 4 | 2 | 1 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Dec 2021, 28 months.
Results were first posted in Oct 2022, 10 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 28 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab
Tanvex BioPharma USA, Inc.